WVU CANCER CENTER PART OF NATIONAL STUDY ON ANTI-MELANOMA DRUG
Posted on 6/18/2013
HSC 2020 Strategic Plan Priority: Contribute to the health of West Virginians through leading edge research programs that distinguish WVU HSC
MORGANTOWN, W.Va. – Melanoma is one of the most aggressive and sometimes deadly types of skin cancer.
The West Virginia University Mary Babb Randolph Cancer Centeris part of a national study on a drug for melanoma patients whose tumor has been surgically removed but who are high-risk for the melanoma to return.
The only drug currently approved by the Food and Drug Administration (FDA) for these patients is high-dose interferon.The drug in the study underway at the WVU Cancer Center is ipilimumab (pronounced IP i LIM ue mab), an immunotherapy drug that stimulates the body’s immune system to fight melanoma. It has been shown to improve survival in patients with advanced melanoma, which has spread to other organs. However, it is only FDA approved for treatment of advanced melanoma when surgery is not possible.